Clinical Trials

We are developing a robust clinical trial program to test the efficacy and safety of our investigative medicines.

Study	Trial Overview
Program: JANX007 (PSMA x CD3 TRACTr) Status: Active, Recruiting	The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.
Program: JANX008 (EGFR x CD3 TRACTr) Status: Active, Recruiting	The Phase 1 clinical trial is a first-in-human, Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05783622.

Study

Trial Overview

Program:

JANX007 (PSMA x CD3 TRACTr)

Status:

Active, Recruiting

The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC.

For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.

Program:

JANX008 (EGFR x CD3 TRACTr)

Status:

Active, Recruiting

The Phase 1 clinical trial is a first-in-human, Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05783622.

We have a range of precision immuno-oncology programs in development designed to address large numbers of patients in desperate need.

See our pipeline